Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Upstream Bio has raised $200.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Upstream Bio's investors include TCG Crossover, Wellington Management, Samsara BioCapital, OrbiMed, Bain Capital Life Sciences.
Upstream Bio is headquartered in Waltham, United States.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Upstream Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Upstream Bio — Funding & Investors." VCBacked, June 8, 2023, https://www.vcbacked.co/company/upstream-bio. Accessed August 13, 2026.
VCBacked. (2023). Upstream Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/upstream-bio
{{cite web |title=Upstream Bio — Funding & Investors |url=https://www.vcbacked.co/company/upstream-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated